DGX Prints Today With Positioning Already Tilted Bullish

Quest Diagnostics enters its Q3 2026 results this morning as one of the least shorted names among its closest laboratory peers, with short interest at 2.5% of free float, while closest peer LH has edged up 2% over the past week against DGX's 1.7% gain. The broader peer group has been mixed, with OPK surging 16.8% on the week and HQY adding 8.9%, making DGX's comparatively modest move look like a story of steady accumulation rather than momentum chasing.

The options market has pulled back from the extreme call-heavy positioning that defined the two sessions before the original October 22 date. The put/call ratio has recovered to 0.59 from the 52-week low of 0.29 hit earlier this week, though it remains well below the 20-day mean of 0.98. That mean itself has been dragged down by the recent call surge. The shape of the last 30 days tells the full story: the PCR ran above 1.35 through early October, then collapsed as call buyers stepped in aggressively ahead of the print. Short interest has moved in the same direction, falling 8.8% over the past week and 21% over the past month to sit at 2.5% of float. Borrow availability remains near its loosest reading of the past year at 1,755%, meaning roughly 17 shares are available to lend for every one currently borrowed. Nothing in the lending market suggests bears are building a competing position.

The analyst debate focuses on whether volume quality can hold as two major clients, Corewell and Fresenius, continue to weigh on average revenue per requisition. Bulls point to the consumer-initiated testing platform, which contributed nearly $250 million in revenue last quarter and grew 35%, and to cost-saving programmes that have supported margins through a softer reimbursement backdrop. Barclays raised its target to $260 this month while keeping an Overweight. Sceptics, including UBS and Truist, have also lifted targets in recent months, to $245 and $260 respectively, but from a Hold position. The mean target of $254 sits modestly above the current price of $243, leaving little room for error if volume trends disappoint. T. Rowe Price trimmed its stake from 6.5% to 4.9% earlier this year, a quiet but notable reduction from one of the larger active holders on the register.

The print will test whether the 35%-growth consumer testing business can continue to offset the drag from institutional client volume losses, and whether that combination produces margins the Street finds convincing at a 20.5x trailing earnings multiple.